NeuroPace appoints Lisa Andrade as Class II director, replacing Evan Norton

NeuroPace Inc

Evan Norton resigned as Class II director effective Nov 1, 2021; no disagreement cited.
Lisa Andrade appointed as Class II director effective Nov 1, 2021, term through 2023 annual meeting.
Andrade will serve on Audit and Compensation Committees.
She receives a stock option with $185K grant-date fair value, monthly vesting over 3 years.
Annual cash retainers: $40K board, $10K audit, $7,500 compensation.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Lisa Andrade

Class II director

NPCE · NeuroPace Inc

Effective: 2021-11-01
Filed: October 19, 2021, 7:59 PM ET

On October 15, 2021, the Board appointed Lisa Andrade as a Class II director to fill the vacancy created by Mr. Norton’s resignation, effective as of November 1, 2021.

Departed

Evan Norton

Class II director

NPCE · NeuroPace Inc

Effective: 2021-11-01
Successor: Lisa Andrade
Filed: October 19, 2021, 7:59 PM ET

On October 14, 2021, Evan Norton, a Class II director, resigned from the Board of Directors (the “Board”) (including the Compensation Committee and Audit Committee) of NeuroPace, Inc., effective as of November 1, 2021.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Lisa Andrade was appointed as Class II director at NeuroPace Inc.

Action: appointed
Role: Class II director

Exact text from the filing

On October 15, 2021, the Board appointed Lisa Andrade as a Class II director to fill the vacancy created by Mr. Norton’s resignation, effective as of November 1, 2021.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Evan Norton resigned as Class II director at NeuroPace Inc.

Action: resigned
Role: Class II director

Exact text from the filing

On October 14, 2021, Evan Norton, a Class II director, resigned from the Board of Directors (the “Board”) (including the Compensation Committee and Audit Committee) of NeuroPace, Inc., effective as of November 1, 2021.

View on SEC.gov

NeuroPace Inc filing history →

Source: SEC EDGAR

accession 0001193125-21-302022

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.